omniture
和铂医药(苏州)有限公司 Harbour BioMed

Latest News

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Oct. 19, 2021 /PRNewswire/ -- Harbou...

2021-10-19 17:52 987

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbo...

2021-09-27 21:03 3852

Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbo...

2021-09-13 14:34 2072

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 1, 2021 /PRNewswire/ -- Harbou...

2021-09-01 13:05 1759

Harbour BioMed Reports 2021 Interim Results

CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour...

2021-08-31 13:47 2702

HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbou...

2021-07-26 19:11 3977

Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 20, 2021 /PRNewswire/ -- Harbou...

2021-07-20 21:53 11937

Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persiste...

2021-07-06 21:06 17296

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbou...

2021-06-17 15:41 13107

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbou...

2021-06-16 13:08 7723

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ -- Harbour...

2021-05-11 18:10 3965

Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour ...

2021-04-13 14:55 2637

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today...

2021-03-22 10:31 3107

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI and SUZHOU, China, March 12, 2021 /PRNewsw...

2021-03-12 09:00 4038

Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbou...

2021-02-26 10:16 5192

Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Harbour B...

2021-01-28 12:54 5136

Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

CAMBRIDGE, Mass. and SUZHOU, China, Dec. 17, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour ...

2020-12-17 08:19 9530

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, Netherlands, Dec. 15, 2020 /PRNewswire/ -- Harbour BioMed...

2020-12-15 08:00 5427

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or int...

2020-12-09 17:29 4832
12